Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 213

1.

Severity of depression and response to antidepressants and placebo: an analysis of the Food and Drug Administration database.

Khan A, Leventhal RM, Khan SR, Brown WA.

J Clin Psychopharmacol. 2002 Feb;22(1):40-5.

PMID:
11799341
2.

Placebo response and antidepressant clinical trial outcome.

Khan A, Detke M, Khan SR, Mallinckrodt C.

J Nerv Ment Dis. 2003 Apr;191(4):211-8.

PMID:
12695731
3.

Relationship between depression severity entry criteria and antidepressant clinical trial outcomes.

Khan A, Schwartz K, Kolts RL, Ridgway D, Lineberry C.

Biol Psychiatry. 2007 Jul 1;62(1):65-71. Epub 2006 Dec 4.

PMID:
17141744
4.

Exploratory analyses of efficacy data from major depressive disorder trials submitted to the US Food and Drug Administration in support of new drug applications.

Khin NA, Chen YF, Yang Y, Yang P, Laughren TP.

J Clin Psychiatry. 2011 Apr;72(4):464-72. doi: 10.4088/JCP.10m06191. Erratum in: J Clin Psychiatry. 2011 Jun;72(6):874.

PMID:
21527123
5.

Severity of depressive symptoms and response to antidepressants and placebo in antidepressant trials.

Khan A, Brodhead AE, Kolts RL, Brown WA.

J Psychiatr Res. 2005 Mar;39(2):145-50.

PMID:
15589562
8.

Effectiveness of low doses of paroxetine controlled release in the treatment of major depressive disorder.

Trivedi MH, Pigotti TA, Perera P, Dillingham KE, Carfagno ML, Pitts CD.

J Clin Psychiatry. 2004 Oct;65(10):1356-64.

PMID:
15491239
9.

The effect of duloxetine on painful physical symptoms in depressed patients: do improvements in these symptoms result in higher remission rates?

Fava M, Mallinckrodt CH, Detke MJ, Watkin JG, Wohlreich MM.

J Clin Psychiatry. 2004 Apr;65(4):521-30.

PMID:
15119915
11.

Why has the antidepressant-placebo difference in antidepressant clinical trials diminished over the past three decades?

Khan A, Bhat A, Kolts R, Thase ME, Brown W.

CNS Neurosci Ther. 2010 Aug;16(4):217-26. doi: 10.1111/j.1755-5949.2010.00151.x. Epub 2010 Apr 16.

PMID:
20406269
12.

[Antidepressants and their onset of action: a major clinical, methodological and pronostical issue].

Gourion D.

Encephale. 2008 Jan;34(1):73-81. doi: 10.1016/j.encep.2007.12.001. Epub 2008 Feb 5. Review. French.

PMID:
18514154
13.

Factors that influence the outcome of placebo-controlled antidepressant clinical trials.

Niklson IA, Reimitz PE, Sennef C.

Psychopharmacol Bull. 1997;33(1):41-51.

PMID:
9133750
14.

[Escitalopram is more effective than citalopram for the treatment of severe major depressive disorder].

Azorin JM, Llorca PM, Despiegel N, Verpillat P.

Encephale. 2004 Mar-Apr;30(2):158-66. French.

PMID:
15107719
15.

Duloxetine: a review of its use in the treatment of generalized anxiety disorder.

Carter NJ, McCormack PL.

CNS Drugs. 2009;23(6):523-41. doi: 10.2165/00023210-200923060-00006. Review.

PMID:
19480470
16.

Dose-response relationship of duloxetine in placebo-controlled clinical trials in patients with major depressive disorder.

Bech P, Kajdasz DK, Porsdal V.

Psychopharmacology (Berl). 2006 Oct;188(3):273-80. Epub 2006 Sep 8.

PMID:
16960699
17.

[Use of antidepressant drugs in schizophrenic patients with depression].

Micallef J, Fakra E, Blin O.

Encephale. 2006 Mar-Apr;32(2 Pt 1):263-9. Review. French.

PMID:
16910628
19.

A comparative meta-analysis of Clinical Global Impressions change in antidepressant trials.

Spielmans GI, McFall JP.

J Nerv Ment Dis. 2006 Nov;194(11):845-52.

PMID:
17102709
20.

Severe depression and antidepressants: focus on a pooled analysis of placebo-controlled studies on agomelatine.

Montgomery SA, Kasper S.

Int Clin Psychopharmacol. 2007 Sep;22(5):283-91.

PMID:
17690597

Supplemental Content

Support Center